ESR1 and triple-negative breast carcinoma: Our follow-up study revealed that the expression of WBP2 is higher in Epidermal Growth Factor Receptor 2 (HER2)+ and triple-negative breast cancer (TNBC) cell lines compared with the less aggressive estrogen receptor (ER)+ cell lines like MCF-7 [13].